SIGA Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Nine-month product revenue was $42M, with no Q3 product sales, and the quarter ended with $116M cash and no debt. A five-year Canadian contract adds up to $15M, while U.S. procurement timing remains uncertain and the PEP filing is delayed to 2028.
-
Q2 2026 saw $38M in product revenues, driven by U.S. and international TPOXX deliveries, with net income of $12M and strong cash reserves. Progress continues on new U.S. contracts and international expansion, despite slower government procurement cycles.
-
The meeting reviewed strong 2025 financials, highlighted strategic advances in TPOXX development, and approved all shareholder proposals, including board elections, auditor ratification, executive compensation, and a stock incentive plan amendment. Dividends and preparedness initiatives were emphasized.
-
Minimal Q1 deliveries led to a net loss, but a strong cash position enabled a special dividend. International expansion continues with a $13M Asia Pacific order and a new MENA partnership, while long-term outlook remains positive amid ongoing government engagement.
Fiscal Year 2025
-
2025 saw $88M in product revenue, $23M net income, and a $155M cash balance with no debt. U.S. and international demand for TPOXX remains strong, with new multi-year contracts and ongoing regulatory engagement in Europe. Capital allocation remains disciplined.
-
Product revenue for the first nine months of 2025 rose to $86 million, with strong U.S. government and international sales. Cash remains robust at $172 million and no debt, supporting ongoing R&D and shareholder returns. Ongoing government engagement and pipeline progress position the company for future growth.
-
Q2 2025 saw $79 million in product revenues, strong government funding, and robust net income. Regulatory and international expansion efforts continue, with a solid cash position and no debt. EMA review and U.S. procurement timing remain key uncertainties.
-
Q1 2025 saw $6M in product revenue, strong international growth, and major U.S. government orders. Cash remains robust at $162M with no debt, and a $0.60 special dividend was declared. Regulatory and pipeline progress continues, with no tariff impact to date.
Fiscal Year 2024
-
2024 saw record product sales of $133 million, strong profitability, and expanded international reach, including new regulatory approvals and strategic partnerships. Outstanding orders of $70 million are set for 2025 delivery, and a capital management decision is expected in Q2.
-
Q3 2024 saw strong revenue growth, with $122 million in new orders and $53 million in nine-month product revenue, driven by U.S. and international TPOXX sales. Outstanding orders of $146 million support robust outlook for Q4 and 2025, while pipeline expansion and regulatory progress continue.
-
Q2 and H1 2024 revenues surged year-over-year, driven by strong U.S. and international TPOXX sales. A $113M BARDA contract option was exercised, and a special dividend was paid. Ongoing clinical trials and new international agreements support a positive outlook.